These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 17315287)
21. Pancreatic cancer: current and future treatment strategies. Pliarchopoulou K; Pectasides D Cancer Treat Rev; 2009 Aug; 35(5):431-6. PubMed ID: 19328630 [TBL] [Abstract][Full Text] [Related]
22. Can we move towards personalised pancreatic cancer therapy? Jamieson NB; Chang DK; Grimmond SM; Biankin AV Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):335-8. PubMed ID: 24702631 [No Abstract] [Full Text] [Related]
23. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Wang L; Niu W JAMA Surg; 2023 Jan; 158(1):102-103. PubMed ID: 36223123 [No Abstract] [Full Text] [Related]
24. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma-Reply. Shoucair S; Yu J JAMA Surg; 2023 Jan; 158(1):103-104. PubMed ID: 36223124 [No Abstract] [Full Text] [Related]
26. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Stessin AM; Meyer JE; Sherr DL Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501 [TBL] [Abstract][Full Text] [Related]
27. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Nagata S; Jin YF; Yoshizato K; Tomoeda M; Song M; Iizuka N; Kitamura M; Takahashi H; Eguchi H; Ohigashi H; Ishikawa O; Tomita Y Ann Surg Oncol; 2009 Sep; 16(9):2531-8. PubMed ID: 19499276 [TBL] [Abstract][Full Text] [Related]
29. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215 [TBL] [Abstract][Full Text] [Related]
30. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Golcher H; Brunner T; Grabenbauer G; Merkel S; Papadopoulos T; Hohenberger W; Meyer T Eur J Surg Oncol; 2008 Jul; 34(7):756-64. PubMed ID: 18191528 [TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873 [TBL] [Abstract][Full Text] [Related]
32. Adjuvant therapy for pancreatic cancer: a review. Zuckerman DS; Ryan DP Cancer; 2008 Jan; 112(2):243-9. PubMed ID: 18050292 [TBL] [Abstract][Full Text] [Related]
33. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336 [TBL] [Abstract][Full Text] [Related]
40. Multidisciplinary approach to tumors of the pancreas and biliary tree. Brown KM Surg Clin North Am; 2009 Feb; 89(1):115-31, ix. PubMed ID: 19186234 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]